BLFS - BioLife Solutions, Inc.
| Previous Close | 21.26 |
| Open | 21.24 |
| Bid | 19.60 x 800 |
| Ask | 20.44 x 800 |
| Day's Range | 19.45 - 22.38 |
| 52 Week Range | 4.85 - 26.35 |
| Volume | 322,801 |
| Avg. Volume | 172,809 |
| Market Cap | 361.301M |
| Beta (3Y Monthly) | 2.25 |
| PE Ratio (TTM) | 139.50 |
| EPS (TTM) | 0.14 |
| Earnings Date | Mar 6, 2019 - Mar 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.25 |
- Thomson Reuters StreetEvents•3 days ago
Edited Transcript of BLFS earnings conference call or presentation 14-Mar-19 8:30pm GMT
Q4 2018 Biolife Solutions Inc Earnings Call
- GuruFocus.com•8 days ago
BioLife Solutions Inc (BLFS) Files 10-K for the Fiscal Year Ended on December 31, 2018
BioLife Solutions Inc manufactures proprietary and generic cGMP biopreservation media products, generic formulations of blood stem cell freezing media products, custom product formulation packaging services and contract aseptic manufacturing formulation. BioLife Solutions Inc had annual average EBITDA growth of 7.40% over the past ten years. Warning! GuruFocus has detected 2 Warning Signs with BLFS.
Motley Fool•9 days agoBiolife Solutions Inc (BLFS) Q4 2018 Earnings Conference Call Transcript
BLFS earnings call for the period ending December 31, 2018.
- PR Newswire•9 days ago
BioLife Solutions Announces Fourth Quarter and Full Year 2018 Financial Results
Revenue Increased 79% for the Year to $19.7 Million Net Income of $2.9 Million Gained 84 New Direct Cell & Gene Therapy Customers Conference Call and Webcast Begin at 4:30 p.m. Eastern Time Today BOTHELL, ...
- PR Newswire•9 days ago
BioLife Solutions Expands Cell and Gene Therapy Tools Portfolio with Acquisition of Astero Bio
Gains products that automate the thawing process for high-value biologic therapies Provides access to addressable market projected to exceed $150 million by 2024 Conference call and webcast begin at 4:30 ...
- PR Newswire•19 days ago
BioLife Solutions to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Business Update on March 14, 2019
BOTHELL, Wash. , March 4, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and ...
- PR Newswire•last month
BioLife Solutions to Attend and Present at Upcoming Investor and Scientific Conferences
BOTHELL, Wash. , Feb. 19, 2019 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary biopreservation media products ...
- Zacks•last month
Here's Why You Should Invest in Stryker (SYK) Stock Right Now
Stryker's (SYK) strong guidance for the first quarter of 2019 buoys optimism in the stock.
- Zacks•2 months ago
Medical Products Industry Outlook: Plenty of Upside Left
Medical Products Industry Outlook: Plenty of Upside Left
- PR Newswire•2 months ago
SAVSU Technologies Launches Two New evo® Smart Shipper Models to Improve Apheresis Collection Shipments and Cryopreserved Cell and Gene Therapies
evo ACS™ Extends Thermal Protection During Shipment of Patients' T Cells for Downstream Manufacturing of CAR T-Cell Therapies DV7™ Liquid Nitrogen Dewar Offers 7 Days Frozen Storage in a Compact, Non-palletized ...
- PR Newswire•2 months ago
New Policies to Advance Development of Cell and Gene Therapies Announced by FDA
BOTHELL, Wash., Jan. 22, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, expects to benefit from new policies to advance the development of safe and effective cell and gene therapies as set forth in a statement issued by the U.S. Food and Drug Administration (FDA) on January 15, 2019.
- Zacks•2 months ago
Medical Products Industry Gathering Steam: 3 Stocks to Buy
The Medical Products market is gaining traction from a firm exposure to robotics, medical mechatronics and the bipartisan two-year suspension of a 2.3% excise tax on MedTech manufacturers.
- GlobeNewswire•3 months ago
Consolidated Research: 2018 Summary Expectations for Enbridge Energy Partners, Sprouts Farmers Market, BioLife Solutions, PagSeguro Digital, NutriSystem, and Employers — Fundamental Analysis, Key Performance Indications
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of BLFS earnings conference call or presentation 8-Nov-18 9:30pm GMT
Q3 2018 Biolife Solutions Inc Earnings Call
- PR Newswire•4 months ago
BioLife Solutions Completes Redemption of Series A Preferred Stock
Redemption eliminates annual cash dividend payment BOTHELL, Wash. , Nov. 27, 2018 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary ...
- PR Newswire•4 months ago
BioLife Solutions to Attend and Present at Upcoming Scientific and Investor Conferences
BOTHELL, Wash. , Nov. 13, 2018 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary biopreservation media products ...
- PR Newswire•4 months ago
BioLife Solutions Announces Third Quarter 2018 Financial Results
Revenue increases 79% to a record $5.3 million ; achieves net income of $1.2 million Conference call and webcast begin at 4:30 p.m. Eastern time today BOTHELL, Wash. , Nov. 8, 2018 /PRNewswire/ -- BioLife ...
- Zacks•5 months ago
BioLife (BLFS) to Report Q3 Earnings: What's in the Cards?
BioLife (BLFS) is likely to gain from solid segmental revenues in Q3.
- PR Newswire•5 months ago
SAVSU Technologies to Supply evo® Cold Chain Technologies to AveXis
Temperature Sensitive Gene Therapy Protected by Cloud-Connected Smart Shipper and evo.is Cloud App for Real Time Distribution Visibility and Management ALBUQUERQUE, N.M. , Nov. 5, 2018 /PRNewswire/ -- SAVSU ...
- PR Newswire•5 months ago
BioLife Solutions to Report Third Quarter 2018 Financial Results and Provide Business Update on November 8, 2018
BOTHELL, Wash. , Nov. 1, 2018 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" ...
- Zacks•6 months ago
BioLife Solutions Sees Hammer Chart Pattern: Time to Buy?
BioLife Solutions has been struggling lately, but the selling pressure may be coming to an end soon.
- PR Newswire•6 months ago
BioLife Solutions Reports Record Third Quarter 2018 Preliminary Revenue of $5.3 Million, up 79% Year-over-Year
BOTHELL, Wash., Oct. 1, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today reported preliminary revenue for the three months ended September 30, 2018 and provided updated revenue guidance for the full year of 2018. Third quarter 2018 preliminary revenue from sales of BioLife's biopreservation media products reached a record $5.3 million, representing a 79% increase over the third quarter of 2017. BioLife CEO Mike Rice commented, "Strong product demand continued in the third quarter of 2018, with sustained growth from our two most strategic revenue segments.
- Zacks•6 months ago
Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year?
Is (BLFS) Outperforming Other Medical Stocks This Year?
Market Realist•6 months agoAnalysts Still Bullish about BioLife Solutions
BioLife Solutions (BLFS) generated a net income of $1.05 million in the second quarter compared to a net loss of $768,212 in the second quarter of 2017. That translates to net income per share of $0.05 in the second quarter. Its net loss per share was $0.06 in the second quarter of 2017.
